Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases

[1]  I. Lowy,et al.  An analysis of the effectiveness of specific guidelines for the management of ipilimumab-mediated diarrhea/colitis: Prevention of gastrointestinal perforation and/or colectomy , 2008 .

[2]  A. Pavlick,et al.  Disease control and long-term survival in chemotherapy-naive patients with advanced melanoma treated with ipilimumab (MDX- 010) with or without dacarbazine , 2008 .

[3]  J. Wolchok,et al.  Antitumor response and new lesions in advanced melanoma patients on ipilimumab treatment , 2008 .

[4]  H. Pehamberger,et al.  Novel efficacy criteria for antitumor activity to immunotherapy using the example of ipilimumab, an anti-CTLA-4 monoclonal antibody , 2008 .

[5]  S. O’Day,et al.  Targeting cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) , 2007, Cancer.

[6]  J. Kirkwood,et al.  Management of metastatic melanoma. , 2007, Seminars in oncology.

[7]  J. Kirkwood,et al.  Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  S. O’Day,et al.  7005 ORAL Ipilimumab (MDX-010) in patients with stage III/IV melanoma: kinetics and duration of response , 2007 .

[9]  S. O’Day,et al.  7003 ORAL Ipilimumab (MDX-010) in patients with unresectable stage III or IV malignant melanoma: efficacy and safety data from a phase I trial , 2007 .

[10]  J. Weber.  Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. , 2007, The oncologist.

[11]  S. O’Day,et al.  The efficacy and safety of ipilimumab (MDX-010) in patients with unresectable stage III or stage IV malignant melanoma , 2007 .

[12]  A. Sasse,et al.  Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. , 2007, The Cochrane database of systematic reviews.

[13]  S. Rosenberg,et al.  Intrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic Melanoma , 2006, Journal of immunotherapy.

[14]  S. Targan,et al.  Phase II trial of extended dose anti-CTLA-4 antibody ipilimumab (formerly MDX-010) with a multi-peptide vaccine for resected stages IIIC and IV melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Feldman,et al.  Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  S. O’Day,et al.  Management of metastatic melanoma 2005. , 2006, Surgical oncology clinics of North America.

[17]  S. Rosenberg,et al.  Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  A. Pavlick,et al.  DURABLE RESPONSES AND LONG-TERM PROGRESSION- FREE SURVIVAL OBSERVED IN A PHASE II STUDY OF MDX- 010 ALONE OR IN COMBINATION WITH DACARBAZINE (DTIC) IN METASTATIC MELANOMA. , 2005 .

[19]  S. Agarwala.  Relevance and Necessity of Studies on Second-Line Chemotherapy in Melanoma , 2004, Oncology Research and Treatment.

[20]  R. Fisher,et al.  High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Gordon.  Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4 , 2008 .

[22]  J. Wolchok,et al.  The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. , 2008, Cancer immunity.